摘要： 临床对于失代偿期肝硬化主要是针对各种并发症的预防和治疗。随着人们对肝硬化病理生理学认识的不断加深,近年来出现了新的治疗方法和管理策略。然而,在肝硬化并发症管理的许多方面,临床证据尚不清楚,国际指南的推荐意见也不尽相同。本文结合文献对一些具有争议的话题进行综述,旨在为肝硬化并发症的管理提供参考。
冯丽娟, 贾继东. 关于肝硬化并发症诊治的共识与争议[J]. 肝脏, 2022, 27(1): 4-7.
| [1] European Association for The Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol, 2018, 69: 406-460. [2] Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2021, 74: 1014-1048. [3] 中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南.临床肝胆病杂志2017,33:1847-1863. [4] Yoshiji H, Nagoshi S, Akahane T, et al. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol, 2021, 56: 593-619. [5] Uojima H, Hidaka H, Tanaka Y, et al. Furosemide Dose Changes Associated with Furosemide/Tolvaptan Combination Therapy in Patients with Cirrhosis. Dig Dis, 2020, 38: 38-45. [6] Bellos I, Kontzoglou K, Psyrri A, et al. Tolvaptan Response Improves Overall Survival in Patients with Refractory Ascites: A Meta-Analysis. Dig Dis, 2020, 38: 320-328. [7] Hiramine Y, Uto H, Mawatari S, et al. Effect of tolvaptan on the prognosis of patients with hepatic ascites. Hepatol Res, 2019, 49: 765-777. [8] Wang YF, Tang JT, Han T, et al. Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trial. J Dig Dis, 2018, 19: 144-154. [9] Tang J, Wang Y, Han T, et al. Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial. BMC Gastroenterol, 2020, 20: 391. [10] Jia J D, Xie W, Ding H G, et al. Utility and safety of tolvaptan in cirrhotic patients with hyponatremia: A prospective cohort study. Ann Hepatol, 2017, 16: 123-132. [11] Yu YT, Liu J, Hu B, et al. Expert consensus on the use of human serum albumin in critically ill patients. Chin Med J (Engl), 2021, 134: 1639-1654. [12] Lungren MP, Kim CY, Stewart JK, et al. Tunneled peritoneal drainage catheter placement for refractory ascites: single-center experience in 188 patients. J Vasc Interv Radiol, 2013, 24: 1303-1308. [13] Kathpalia P, Bhatia A, Robertazzi S, et al. Indwelling peritoneal catheters in patients with cirrhosis and refractory ascites. Intern Med J, 2015, 45: 1026-1031. [14] Corrigan M, Thomas R, Mcdonagh J, et al. Tunnelled peritoneal drainage catheter placement for the palliative management of refractory ascites in patients with liver cirrhosis. Frontline Gastroenterol, 2021, 12: 108-112. [15] Stratmann K, Fitting D, Zeuzem S, et al. Establishing an indwelling peritoneal catheter as a standard procedure for hospitalized patients with ascites: Retrospective data on feasibility, effectiveness and safety. United European Gastroenterol J, 2019, 7: 673-681. [16] Solbach P, Honer ZU Siederdissen C, Taubert R, et al. Home-based drainage of refractory ascites by a permanent-tunneled peritoneal catheter can safely replace large-volume paracentesis. Eur J Gastroenterol Hepatol, 2017, 29: 539-546. [17] Macken L, Hashim A, Mason L, et al. Permanent indwelling peritoneal catheters for palliation of refractory ascites in end-stage liver disease: A systematic review. Liver Int, 2019, 39: 1594-1607. [18] Macken L, Bremner S, Gage H, et al. Randomised clinical trial: palliative long-term abdominal drains vs large-volume paracentesis in refractory ascites due to cirrhosis. Aliment Pharmacol Ther, 2020, 52: 107-122. [19] Bernardi M, Angeli P, Claria J, et al. Albumin in decompensated cirrhosis: new concepts and perspectives. Gut, 2020, 69: 1127-1138. [20] Caraceni P, Riggio O, Angeli P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER) an open-label randomised trial.pdf. Lancet, 2018,391:2417-2429. [21] Di Pascoli M, Fasolato S, Piano S, et al. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites. Liver Int, 2019, 39: 98-105. [22] Caraceni P, Tufoni M, Zaccherini G, et al. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. J Hepatol, 2021, 74: 340-349. [23] China L, Freemantle N, Forrest E, et al. A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis. N Engl J Med, 2021, 384: 808-817. [24] Solà E, Solé C, Simón-Talero M, et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. J Hepatol, 2018, 69: 1250-1259. [25] Sandi BB, Le?o GS, de Mattos AA, et al. Long-term albumin administration in patients with cirrhosis and ascites: a metaanalysis of randomized controlled trials. J Hepatol, 2021, 36:609-617. [26] Sharma M, Singh S, Desai V, et al. Comparison of Therapies for Primary Prevention of Esophageal Variceal Bleeding: A Systematic Review and Network Meta-analysis. Hepatology, 2019, 69: 1657-1675. [27] Serste T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology, 2010, 52: 1017-1022. [28] Krag A, Moller S, Burroughs AK, et al. Betablockers induce cardiac chronotropic incompetence. J Hepatol, 2012, 56: 298-299. [29] Ferrarese A, Tikhonoff V, Casiglia E, et al. Hemodynamic Evaluation of Nonselective beta-Blockers in Patients with Cirrhosis and Refractory Ascites. Gastroenterol Res Pract, 2018, 2018: 4098210. [30] Krag A, Wiest R, Albillos A, et al. The window hypothesis: haemodynamic and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease. Gut, 2012, 61: 967-969. [31] Krag A, Wiest R, Albillos A, et al. The window hypothesis: haemodynamic and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease. Gut, 2012, 61: 967-969. [32] Chirapongsathorn S, Valentin N, Alahdab F, et al. Nonselective beta-Blockers and Survival in Patients With Cirrhosis and Ascites: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol, 2016, 14: 1096-104,e9. [33] Bossen L, Krag A, Vilstrup H, et al. Nonselective beta-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients. Hepatology, 2016, 63: 1968-1976. [34] Kang SH, Lee M, Kim MY, et al. The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study. Hepatol Int, 2021, 15: 424-436. [35] De Franchis R, Baveno VIF. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol, 2015, 63: 743-752. [36] Thiele M, Albillos A, Abazi R, et al. Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials. Liver Int, 2015, 35: 2009-2016. [37] Yoon KT, Liu H, Lee SS. beta-blockers in advanced cirrhosis: More friend than enemy. Clin Mol Hepatol, 2021, 27: 425-436. [38] Boyer TD, Sanyal AJ, Wong F, et al. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. Gastroenterology, 2016, 150: 1579-1589 e2. [39] Wong F, Pappas SC, Curry MP, et al. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. N Engl J Med, 2021, 384: 818-828. [40] Thomson MJ, Taylor A, Sharma P, et al. Limited Progress in Hepatorenal Syndrome (HRS) Reversal and Survival 2002-2018: A Systematic Review and Meta-Analysis. Dig Dis Sci, 2020, 65: 1539-1548. [41] Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology, 2015, 62: 567-574. [42] Mohamed MMG, Rauf A, Adam A, et al. Terlipressin effect on hepatorenal syndrome: Updated meta-analysis of randomized controlled trials. JGH Open, 2021, 5: 896-901. [43] Sharma P, Moore K, Ganger D, et al. Role of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation. Liver Transpl, 2020, 26: 1328-1336. |
| [1] | 宦红娣. 肝硬化患者中急性肾损伤的代谢组学研究[J]. 肝脏, 2022, 27(1): 15-16. |
| [2] | 张昕, 吕丹, 刘丹阳. 肝硬化食管胃底静脉曲张破裂出血伴缺血性肝炎的危险因素分析[J]. 肝脏, 2022, 27(1): 47-50. |
| [3] | 肖琨, 刘爱华, 刘琨. 超声测量静脉内径在血吸虫肝硬化及乙型肝炎肝硬化鉴别中的应用[J]. 肝脏, 2022, 27(1): 51-53. |
| [4] | 李旭东, 范锡伟, 王丽, 郭振凯. HBV相关慢加急性肝衰竭出血事件预后评价及影响因素分析[J]. 肝脏, 2022, 27(1): 68-71. |
| [5] | 冯丹妮, 张达利, 贺希, 张晓峰, 牛晓峰, 李志杰, 李丽昕, 刘佳, 庄云龙, 刘振文, 王洪波. 肝移植术后新发非酒精性脂肪肝的危险因素[J]. 肝脏, 2022, 27(1): 95-97. |
| [6] | 王希, 谭善忠. 肝硬化并发感染的机制研究现状[J]. 肝脏, 2022, 27(1): 120-122. |
| [7] | 张丽丽, 胡建华, 张纯, 杨君, 吕文良. 酒精性肝硬化合并强直性脊柱炎并存类风湿关节炎1例[J]. 肝脏, 2022, 27(1): 124-125. |
| [8] | 张云, 尹伟, 郭洪雷, 李成忠. 新型生物学标志物在肝硬化AKI早期诊断和鉴别诊断中的研究进展[J]. 肝脏, 2021, 26(9): 953-955. |
| [9] | 潘国栋, 侯斐, 张瑶, 刘玉凤, 王晓静, 刘尧, 段英, 王艳斌, 李炜, 郝一炜, 熊号峰. 右心声学造影在肝硬化患者肺内血管分流评价中的应用[J]. 肝脏, 2021, 26(9): 972-976. |
| [10] | 黎美琳, 姚上志, 王栋, 居峰, 王晓伟. 卡维地络联合内镜下精准食管胃静脉曲张断流术治疗食管胃静脉曲张破裂出血的疗效[J]. 肝脏, 2021, 26(9): 980-983. |
| [11] | 陈衍磊, 蔡永国. 超声内镜下内镜黏膜剥离术在乙型肝炎肝硬化患者食管良性肿瘤中的可行性研究[J]. 肝脏, 2021, 26(9): 984-986. |
| [12] | 张必全, 马宇航. CT灌注相关参数定量预测血吸虫性肝硬化患者预后的价值[J]. 肝脏, 2021, 26(9): 987-989. |
| [13] | 王开乐, 金贤德, 王甄, 张欣, 周杰. 多模态影像定量参数在肝硬化背景下小肝癌及增生结节的鉴别诊断价值[J]. 肝脏, 2021, 26(8): 861-865. |
| [14] | 周佳美, 班志超, 张晓娟, 李艳, 张咏华, 王明蕾, 王会哲, 张欣. LSPS评分评估酒精性肝硬化并发食管胃底静脉曲张出血患者短期预后的价值[J]. 肝脏, 2021, 26(8): 874-878. |
| [15] | 赵宏伟, 祝佳, 张国良, 白雪峰, 韩飞, 林光耀. 原发性胆汁性胆管炎患者磁共振检查肝脏表现特点分析[J]. 肝脏, 2021, 26(8): 903-906. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
